Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563274 | 0.90 | PPARA (0.41) | PPARASLC22A12GABRA5GABRB2HSD17B10 | |
| SCHEMBL2409115 | 0.87 | PPARA (0.39) | PPARASLC22A12MAPT | |
| SCHEMBL2413527 | 0.84 | AOC3 (0.36) | PPARAAOC3HDAC1HDAC6 | |
| SCHEMBL12275265 | 0.84 | AOC3 (0.36) | AOC3HDAC1HDAC6MAPT | |
| SCHEMBL2415348 | 0.82 | HSD17B10 (0.49) | PPARAGABRA5GABRB2HSD17B10MAPT | |
| SCHEMBL2415156 | 0.78 | MAPT (0.42) | PPARAHSD17B10MAPT | |
| SCHEMBL2411454 | 0.77 | PPARA (0.36) | PPARASLC22A12MAPT | |
| SCHEMBL2409372 | 0.77 | AOC3 (0.32) | AOC3 | |
| SCHEMBL2415222 | 0.76 | S1PR1 (0.37) | PPARAMAPT | |
| SCHEMBL2412843 | 0.76 | NPC1 (0.41) | PPARASLC22A12HDAC1HDAC6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026370-B2 | Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8026370-B2 | Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | MITSUBISHI PHAMA CORPORATION (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1816128-A1 | CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-08-08 | — | — | EP | disclosed |
| EP-1816128-A1 | CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | PPARA, PPARD, PPARG | PPARA 1/4885AOC3 3297/4885SLC22A12 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.